17817-31-1
17817-31-1 結(jié)構(gòu)式
基本信息
4',6,7-三羥基異黃酮
6,7,4'-TRIHYDROXYISOFLAVONE
DEMETHYLTEXASIN
TRIHYDROXYISOFLAVONE, 4',6,7-
TRIHYDROXYISOFLAVONE, 4',6,7-(RG)
6,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
物理化學(xué)性質(zhì)
general analytical
life science and biopharma
metabolomics
安全數(shù)據(jù)
Eye Irrit. 2
Skin Irrit. 2
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/12/22 | HY-N5072 | 4',6,7-三羥異黃酮 Desmethylglycitein | 17817-31-1 | 5mg | 300元 |
| 2025/12/22 | HY-N5072 | 4',6,7-三羥異黃酮 Desmethylglycitein | 17817-31-1 | 10 mM * 1 mLin DMSO | 330元 |
| 2025/12/22 | HY-N5072 | 4',6,7-三羥異黃酮 Desmethylglycitein | 17817-31-1 | 10 mg | 500元 |
常見問題列表
|
CDK1
|
CDK2
|
PKC
|
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity . Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells. Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) .
Cell Viability Assay
| Cell Line: | HCT-116 cells |
| Concentration: | 0, 12.5, 25, 50 or 100 μM |
| Incubation Time: | 24, 48 or 72 hours |
| Result: | Inhibited anchorage-dependent and -independent growth of HCT-116 cells. |
Western Blot Analysis
| Cell Line: | HCT-116 and DLD1 cells |
| Concentration: | 0, 25, 50 or 100 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited CDK1,CDK2 expression. |
Cell Cycle Analysis
| Cell Line: | HCT-116 cells |
| Concentration: | 0, 25, 50 or 100 μM |
| Incubation Time: | 24, 48 or 72 hours |
| Result: | Induces cell cycle arrest of HCT-116 cells at S and G2/M phases. |
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system.
| Animal Model: | Female athymic nude mice subcutaneously injected with HCT-116 cells |
| Dosage: | 5 or 25 mg/kg |
| Administration: | Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days |
| Result: | Decreased tumor growth, volume and weight of HCT-116 xenografts. |